Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.reuma.2020.04.009 http://scihub22266oqcxt.onion/10.1016/j.reuma.2020.04.009 32482538!8041148!32482538     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Reumatol+Clin+(Engl+Ed) 2021 ; 17 (6): 309-312 Nephropedia Template TP {{tp|p=32482538|t=2021. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19 |pdf=|usr=}}{{32482538}} gab.com Text Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19 JO: Reumatol Clin (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=32482538 #FOAvip The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection. Twit Text FOAVip Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19 ????Reumatol Clin (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=32482538 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32482538 #FOAvip English Wikipedia <ref>{{Cite pmid|32482538}}</ref> Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19 #MMPMID32482538 Munoz-Jimenez A; Rubio-Romero E; Marenco de la Fuente JL Reumatol Clin (Engl Ed) 2021[Jun]; 17 (6): 309-312 PMID32482538show ga The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection. |Anti-Inflammatory Agents/*therapeutic use[MESH] |COVID-19/*complications/immunology[MESH] |Cytokine Release Syndrome/*drug therapy/virology[MESH] |Humans[MESH] |Interleukin 1 Receptor Antagonist Protein/*therapeutic use[MESH] |Respiratory Distress Syndrome/*drug therapy/virology[MESH]Propuesta de uso de anakinra en el distres respiratorio agudo secundar(epmc).pdf DeepDyve Pubget Overpricing